Katherine Whitmire
Nurse Practitioner · Las Vegas, NVNPI 1114475357
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (58.3%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Sanofi-aventis U.S. LLC accounts for 92.2% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2022 at $17,720 and has fallen 99.9% since, to $26 in 2025. Among nurse practitioner clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 89 payments — averaging $205.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$17K
- Insulet Corporation$291
- Novo Nordisk$159
- Medtronic$146
- Abbott$141
- Lifescan, Inc.$134
- plus $551 from 12 others
Across 3 payments — averaging $666.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi-aventis U.S. LLC$2K
What the payments were for
- Speaking & faculty fees$5,51330%
- Travel & lodging$10,66258%
- Food & beverage$2,11512%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 24 | $16,868 |
| Insulet Corporation | 10 | $291 |
| Novo Nordisk | 12 | $159 |
| Medtronic | 2 | $146 |
| Abbott | 8 | $141 |
| Lifescan, Inc. | 7 | $134 |
| Dexcom, Inc. | 6 | $117 |
| AbbVie | 4 | $94 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $75 |
| Ascensia Diabetes Care US Inc. | 1 | $67 |
| Mannkind Corporation | 2 | $34 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| AstraZeneca | 2 | $30 |
| Ultragenyx Pharmaceutical Inc. | 1 | $30 |
| Ascendis Pharma Endocrinology Inc | 1 | $22 |
| Impel Pharmaceuticals Inc. | 1 | $20 |
| Biomarin Pharmaceutical Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$15,967
- TOUJEO$688
- ProGrip$129
How this compares
$18,289 in reported general payments places this provider in the 95th percentile of 933 nurse practitioner providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 16 | $25,676 |
| EntrestoSacubitril/Valsartan | 11 | $19,389 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 12 | $15,318 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $12,237 |
| Novolog FlexpenInsulin Aspart | 14 | $3,833 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $2,037 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,139 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 23 | $614 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $449 |
| Gabapentin | 21 | $398 |
| Hydroxyzine Hcl | 21 | $333 |
| Oxycodone Hcl | 21 | $243 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 16 | $241 |
| Trazodone Hcl | 31 | $230 |
| Fluticasone Propionate | 12 | $202 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $16,868 | $15,31812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 933 nurse practitioner providers in Nevada.
Other nurse practitioner in Las Vegas
- Melanie SpeedLas Vegas$80K
- Shelley MilesLas Vegas$34K
- Nasslynne LenzLas Vegas$32K
- Shannon SouthwickLas Vegas$32K
- Bonnie KwanLas Vegas$30K
- Amanda RalphLas Vegas$26K
- Teodoro AgtayLas Vegas$25K
- Jennifer WalshLas Vegas$18K
- Andrew VolinLas Vegas$17K
- John BlakemoreLas Vegas$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.